Merck

Valuation Analysis

About the Company

Merck en bref

Merck (MRK) is currently trading at 112,88 € with a market capitalization of 278,8 Md €. The trailing P/E ratio stands at 36.68x, with a forward P/E of 13.45x. The 52-week range spans from 67,26 € to 117,09 €; the current price is 3.6% below the yearly high. Year-over-year revenue growth stands at +4.9%. The net profit margin stands at 13.59%.

💰 Dividende

Merck pays an annual dividend of 2,95 € per share, representing a yield of 2.61%. The payout ratio stands at 93.52%. The elevated payout ratio reflects a mature dividend policy.

📊 Avis des analystes

26 analystes évaluent Merck (MRK) au consensus : Acheter. L'objectif de cours moyen est de 117,21 €, soit un potentiel de +3.83% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 91,04 € à 134,39 €.

Merck : la thèse d'investissement en détail

Merck (MRK) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 76.73%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Le scénario baissier

Revenue growth has slowed to just 4.9%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

At a PEG of 12.06, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here.

À surveiller

• The forward P/E of 13.45x is meaningfully below the trailing 36.68x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 91.6% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, higher leverage relative to equity.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Merck?

Compare top-rated brokers — low fees, trusted providers, fully regulated.